ClinConnect ClinConnect Logo
Search / Trial NCT04018118

Natural History of Hypereosinophilia and Hypereosinophilic Syndromes

Launched by UNIVERSITY HOSPITAL, LILLE · Jul 10, 2019

Trial Information

Current as of July 27, 2025

Recruiting

Keywords

Eosinophilia Hypereosinophilia Hypereosinophilic Syndrome

ClinConnect Summary

The COHESion study is a clinical trial focused on understanding a condition called hypereosinophilia (HE) and a related group of disorders known as hypereosinophilic syndromes (HES). These conditions involve having high levels of a type of white blood cell called eosinophils, which can affect various organs in the body, such as the heart, lungs, and skin. The trial aims to explore the different characteristics of patients with HE and HES, especially looking into genetic factors that might explain why some people have these conditions without any clear reason, like infections or allergies.

To participate in this study, individuals must have a diagnosis of hypereosinophilia or HES, with specific criteria indicating high eosinophil levels or related organ damage. The trial is open to men and women of any age who are socially insured and willing to give their consent to join. Participants will have the opportunity to contribute to important research that could help improve the understanding and treatment of these conditions. It's important to note that individuals with certain conditions, such as HIV, or those unable to provide informed consent are not eligible for this study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Men or Women of any age :
  • With the diagnosis criteria of hyperosinophlia OR hypereosinophilic syndrome OR specific organ eosinophilic disease according to the consensus conference of the International Cooperative Working Group on Eosinophil Disorders (ICOG-EO)
  • With an AEC \> 1500/mm3 or organ damage related to the presence of eosinophils in the tissues or organs whatever the context (idiopathic, clonal or reactive, including drug-related, parasitic or allergic)
  • HES diagnosis since 2005/01/01
  • Patients socially insured
  • Patient who agreed to participate to the study, its proceedings and duration.
  • Exclusion Criteria:
  • Known HIV infection
  • Not socially insured
  • Person unable to receive a enlighten information
  • Person who refuse to sign the consent
  • Persons deprived of their liberty
  • Persons benefiting from a system of legal protection (tutelage / guardianship)

About University Hospital, Lille

University Hospital Lille is a leading academic medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the hospital leverages its extensive resources, multidisciplinary expertise, and state-of-the-art facilities to facilitate groundbreaking studies across various medical fields. Committed to enhancing therapeutic options and improving patient outcomes, University Hospital Lille collaborates with researchers, healthcare professionals, and industry partners to ensure rigorous scientific standards and ethical practices in all clinical trials.

Locations

Lille, , France

Patients applied

0 patients applied

Trial Officials

Guillaume Lefevre

Principal Investigator

University Hospital, Lille

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials